Yan Yu
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
Papers in
- Oncology 27
- Cancer Immunotherapy and Biomarkers 12
- Cancer Cells and Metastasis 5
- Lung Cancer Research Studies 5
- Cytokine Signaling Pathways and Interactions 4
-
- RNA modifications and cancer 4
- Co-authors
- Yuqin Wang (1 shared paper)Xueqian Wang (1 shared paper)Yang Zhou (1 shared paper)Weitong Gao (1 shared paper)Jingyan Cao (8 shared papers)Ting Sun (2 shared papers)Lin Jiao (1 shared paper)Yangxia Wang (1 shared paper)
- Journals
- Journal of Clinical Oncology (4 papers)Journal of Thoracic Oncology (3 papers)Annals of Oncology (3 papers)Frontiers in Oncology (3 papers)PLoS ONE (3 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Yan Yu
51 papers receiving 2.1k citations
Yan Yu's Hit Papers
Peers
Comparison fields: 5 of 99
- Cancer Research 548
- Oncology 909
- Immunology 448
- Pulmonary and Respiratory Medicine 656
- Molecular Biology 916
Countries citing papers authored by Yan Yu
This map shows the geographic impact of Yan Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Yu more than expected).
Fields of papers citing papers by Yan Yu
This network shows the impact of papers produced by Yan Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Yu. The network helps show where Yan Yu may publish in the future.
Co-authors
The 25 scholars most cited alongside Yan Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy Hit paper breakdown → | 2022 | 690 |
| 2 | Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2021 | 246 |
| 3 | 2018 | 202 | |
| 4 | 2015 | 161 | |
| 5 | Interleukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-κB/ZEB1 signal pathway. | 2015 | 97 |
| 6 | 2019 | 80 | |
| 7 | 2014 | 73 | |
| 8 | 2018 | 53 | |
| 9 | 2011 | 43 | |
| 10 | 2015 | 39 | |
| 11 | 2018 | 34 | |
| 12 | 2015 | 29 | |
| 13 | 2020 | 27 | |
| 14 | 2013 | 24 | |
| 15 | 2018 | 23 | |
| 16 | 2014 | 23 | |
| 17 | 2018 | 22 | |
| 18 | 2019 | 20 | |
| 19 | 2020 | 20 | |
| 20 | 2017 | 18 |
About Yan Yu
Yan Yu is a scholar working on Oncology, Molecular Biology, Cancer Research, Immunology and Pulmonary and Respiratory Medicine, having authored 54 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (12 papers), Cancer Cells and Metastasis (5 papers), Cancer-related molecular mechanisms research (5 papers), Lung Cancer Research Studies (5 papers), Cytokine Signaling Pathways and Interactions (4 papers), Cancer, Lipids, and Metabolism (4 papers), Cancer Genomics and Diagnostics (4 papers) and RNA modifications and cancer (4 papers). The work is most often cited by research in Cancer Research (548 citations), Oncology (909 citations), Immunology (448 citations), Pulmonary and Respiratory Medicine (656 citations) and Molecular Biology (916 citations). Yan Yu has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Yuqin Wang, Xueqian Wang, Yang Zhou, Weitong Gao, Jingyan Cao, Ting Sun, Lin Jiao, Yangxia Wang, Liang Ming and Jin Shi. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Frontiers in Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.